Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Gramegna

In Vitro Antimicrobial Activity of Ceftolozane/Tazobactam Against P. Aeruginosa and Other Non-Fermenting Gram-Negative Organisms in Adults With Cystic Fibrosis

Journal of Global Antimicrobial Resistance

English

Related publications

In Vitro Activity of Ceftazidime–avibactam, Ceftolozane–tazobactam, and Other Comparable Agents Against Clinically Important Gram-Negative Bacilli: Results From the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

Infection and Drug Resistance

Infectious Diseases

Pharmacology

2018

English

In Vitro Susceptibility of Ceftolozane-Tazobactam Against Burkholderia Pseudomallei

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2018

English

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2016

English

In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Clinical Isolates of Enterobacteriaceae and Pseudomonas Aeruginosa: Results From a Multicenter Study in China, 2017

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2019

English

In Vitro Activity of the Trinem Sanfetrinem (GV104326) Against Gram-Positive Organisms.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1996

English

De Novo Design and in Vitro Testing of Antimicrobial Peptides Against Gram-Negative Bacteria

Pharmaceuticals

Molecular Medicine

Pharmaceutical Science

2019

English

Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Meropenem-Resistant Pseudomonas Aeruginosa Isolates

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2016

English

In Vitro Activities of Designed Antimicrobial Peptides Against Multidrug-Resistant Cystic Fibrosis Pathogens

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1999

English

Comparison of Two Culture Methods for Detection of Tobramycin-Resistant Gram-Negative Organisms in the Sputum of Patients With Cystic Fibrosis

Journal of Clinical Microbiology

Microbiology

2002

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Gramegna

In Vitro Antimicrobial Activity of Ceftolozane/Tazobactam Against P. Aeruginosa and Other Non-Fermenting Gram-Negative Organisms in Adults With Cystic Fibrosis

Related publications

In Vitro Activity of Ceftazidime&ndash;avibactam, Ceftolozane&ndash;tazobactam, and Other Comparable Agents Against Clinically Important Gram-Negative Bacilli: Results From the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

In Vitro Susceptibility of Ceftolozane-Tazobactam Against Burkholderia Pseudomallei

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation

In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Clinical Isolates of Enterobacteriaceae and Pseudomonas Aeruginosa: Results From a Multicenter Study in China, 2017

In Vitro Activity of the Trinem Sanfetrinem (GV104326) Against Gram-Positive Organisms.

De Novo Design and in Vitro Testing of Antimicrobial Peptides Against Gram-Negative Bacteria

Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Meropenem-Resistant Pseudomonas Aeruginosa Isolates

In Vitro Activities of Designed Antimicrobial Peptides Against Multidrug-Resistant Cystic Fibrosis Pathogens

Comparison of Two Culture Methods for Detection of Tobramycin-Resistant Gram-Negative Organisms in the Sputum of Patients With Cystic Fibrosis

In Vitro Activity of Ceftazidime–avibactam, Ceftolozane–tazobactam, and Other Comparable Agents Against Clinically Important Gram-Negative Bacilli: Results From the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)